- Home
- ELEV
as 06-06-2025 4:00pm EST
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 18.1M | IPO Year: | 2021 |
| Target Price: | $2.94 | AVG Volume (30 days): | 750.8K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.22 - $3.77 | Next Earning Date: | 08-05-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Elevation Oncology Inc. Common stock News
ELEV Breaking Stock News: Dive into ELEV Ticker-Specific Updates for Smart Investing
PR Newswire
23 days ago
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
Zacks
24 days ago
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
PR Newswire
a month ago
Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
BioPharma Dive
2 months ago
GSK prepares to relaunch Blenrep; Activists challenge another ‘zombie’ biotech
PR Newswire
2 months ago
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
MT Newswires
2 months ago
Stephens Downgrades Elevation Oncology to Equal Weight From Overweight, Adjusts Price Target to $1 From $5
Zacks
3 months ago
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
Investing.com
3 months ago
Elevation Oncology downgraded as it halts lead asset on disappointing trials
Compare ELEV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELEV Elevation Oncology Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.